Page 4 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

1. HER2 POSITIVE DISEASE BURDEN
1.1. Epidemiology of breast cancer (BC)
Global prevalence
1
Prevalence of HER2-positive BC in the population
HER2-positive BC mortality rate according to Surveillance, Epidemiology,
and End Results Program (SEER) data 2015
1.2. Disease burden of BC
Impact of BC on patients
 Compared to the general population, patients with BC experience:

Disease recurrence 4-6 2,3
Suboptimal treatment of early stage BC (eBC) increases the risk of
disease recurrence 15,16

Natural life expectancy for women in high-income countries is
>80 years 15,16

Recurrent BC is responsible for up to two decades median loss of
life-years per patient 15,16
BC recurrence is associated with frequent hospital visits and
interventions, impacting patient HRQoL 17

Nearly 90% of patients with metastatic BC (mBC) will be admitted to
hospital, typically two to four times 17

1.3. Economic burden of BC

Direct and indirect costs associated with BC

Belgium study conclusion 18
 Productivity loss from BC accounted for 89% of the total costs

 Direct costs accounted for 11% of the total costs
 The discounted annual healthcare costs over 6 years were estimated to be
greater for patients with mBC compared to those with eBC

US study conclusion
 Patients with early-stage disease tend to incur lower expenditures than patients

with metastatic presentation 19
 Among the treatment-related costs in the first 12 months after diagnosis,
chemotherapy accounted for the highest percentage to the total claim costs for

Stage IV disease, almost three times higher than in Stage I/II BC 19
 Costs of care were approximately double for patients with BC diagnosed with
distant versus local disease, both in the initial and the last year of life phases

 Treating advanced versus eBC is associated with significant increases in
incremental costs in the US 19

Australian study conclusion
 Indirect costs made up 62% of total BC costs 20

Swedish study conclusion
 Indirect costs constituted 70% of total costs 21

M-AE-00000086 4